Research programme: hepatitis C vaccine - C-PharmaAlternative Names: Bivalent VLP vaccine and adjuvant combination (C-Vaxin) - Cyplasin Biomedical; C-Vaxin; Hepatitis C VLP vaccine - Cyplasin Biomedical
Latest Information Update: 16 Jul 2016
At a glance
- Originator C-Pharma
- Class Hepatitis C vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis C